Novo Nordisk A/S (LON:0TDD)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 122.62B -53.8% |
| Revenue (ttm) | 36.10B +6.4% |
| Net Income | 11.97B +1.4% |
| EPS | 2.69 +1.8% |
| Shares Out | n/a |
| PE Ratio | 10.25 |
| Forward PE | 11.29 |
| Dividend | 1.00 (2.75%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 107,258 |
| Average Volume | 176,298 |
| Open | 35.95 |
| Previous Close | 36.61 |
| Day's Range | 35.63 - 36.82 |
| 52-Week Range | 35.09 - 82.09 |
| Beta | 0.27 |
| RSI | 36.90 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices
New tax will hit branded drugs and active ingredients while exempting generics for at least one year
Novo Nordisk: Competing In A Duopoly
Novo Nordisk A/S (NVO) faces intense competition from Eli Lilly in the fast-growing GLP-1 market, impacting its growth outlook and valuation. NVO's future growth hinges on defending market share with ...
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
71 April Graham Value All-Stars (GVAS): 14 To Buy
The April 2026 GASV list highlights 14 fair-priced, 'safer' mid-to-large-cap value stocks with strong dividend profiles and positive free-cash-flow-yields. Top ten GASV stocks are projected to deliver...
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC ...
Novo Nordisk Releases Data Showing 3.2% Greater Weight Loss vs Lilly Pill
Novo Nordisk Releases Data Showing 3.2% Greater Weight Loss vs Lilly Pill
How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss Launch
Novo Nordisk said Thursday a new study suggests patients prefer its oral Wegovy over Eli Lilly's new GLP-1 pill, Foundayo.
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
Eli Lilly's newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts betting it will quickly narrow Novo Nordisk's head start in the oral market.
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report
The Trump administration is reportedly preparing to announce 100% tariffs on pharmaceutical companies that have not secured pricing deals with the White House . The announcement could come as soon as ...
Jim Cramer on Eli Lilly's recent moves to top Novo Nordisk in the weight loss space
'Mad Money' host Jim Cramer talks recent moves Eli Lilly is making to take the lead in the weight loss race.
Novo VP Weighs In on Approval of Lilly's Obesity Pill
Jamey Millar, executive vice president, US Operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." -------- More ...
Pricing and availability of Novo, Lilly's weight-loss drugs
The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill to enter the fast-growing obesity treatment market.
US approves new oral weight-loss pill developed by Eli Lilly
Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy The US Food and Drug Administration (FDA) gave the green light on Wednesday to a new oral we...
Could This New Approval Be a Turning Point For Novo Nordisk?
Novo Nordisk is launching a new, more effective version of Wegovy. Even with this new approval, the company likely won't catch up to its biggest competitor in the weight loss market.
Novo Nordisk's Wegovy Approved For Cardiovascular Event Risk Reduction In England
(RTTNews) - Novo Nordisk [NVO] announced on Wednesday, that it has received a significant boost after the National Institute for Health and Care Excellence recommended broader use of Wegovy to help pr...
FDA approves lower-cost daily weight loss pill from Eli Lilly
A new daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the FDA approval of Novo Nordisk’s Wegovy pill.
The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
Novo Nordisk stock surges 4%: can NHS boost offset pricing pressure?
Novo Nordisk stock surged on Wednesday after a major policy win, which is seen as a turning point for the drugmaker. England's cost-effectiveness watchdog has backed broader use of Wegovy to cut the r...
Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator
Novo Nordisk weight loss drug Wegovy was recommended by England's drug price regulator to prevent heart attacks and strokes. The new recommendation from NICE will significantly expand access to Wegovy...
British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks
UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's Wegovy to reduce the risk of serious heart problems or strokes in obese or overweight adults, becoming the first GLP-1 drug to be ...
Lilly and Novo Show How AI Is Rewiring Big Pharma
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug ...